Trial Profile
A Phase 1, Open-Label, Dose-Escalation Study of Olaratumab as a Single Agent and in Combination With Doxorubicin, Vincristine/Irinotecan, or High-Dose Ifosfamide in Pediatric Patients With Relapsed or Refractory Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Dec 2021
Price :
$35
*
At a glance
- Drugs Doxorubicin (Primary) ; Ifosfamide (Primary) ; Irinotecan (Primary) ; Olaratumab (Primary) ; Vincristine (Primary)
- Indications CNS cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Eli Lilly and Company (India) Pvt. Ltd
- 06 Jun 2019 Status changed from active, no longer recruiting to completed.
- 02 Jan 2019 Planned End Date changed from 5 Jun 2019 to 30 Nov 2019.
- 02 Jan 2019 Status changed from recruiting to active, no longer recruiting.